PhD Student, Lundbeck Brain Battle 2027
Lundbeck
Summary
Lundbeck is looking for highly motivated MSc candidates to join the Lundbeck Brain Battle, competing for a fully funded industrial PhD project based at Lundbeck in association with a Danish University on studies aiming at discovering new treatments for diseases in the central nervous system. The position spans 3 years and is fully funded by Lundbeck.
Job description
Your new role
Lundbeck is looking for highly motivated MSc candidates to join the Lundbeck Brain Battle, competing for a fully funded industrial PhD project based at Lundbeck in association with a Danish University on studies aiming at discovering new treatments for diseases in the central nervous system. The position spans 3 years and is fully funded by Lundbeck.
This year Brain Battle brings together three ambitious PhD projects at the forefront of neuroscience and drug discovery: integrating human neuro-omics data with experimental studies to uncover the biology and therapeutic potential of orphan GPCRs in neurological and psychiatric disorders; developing humanized Huntington's disease models using patient-derived iPSC neurons in vitro and transplanted into the rat brain to support the development of RNA therapeutics; and leveraging Neuropixels recordings to uncover how abnormal neuronal activity within cerebellar circuits contributes to tremor and ataxia.
As a PhD student at Lundbeck, you will work closely together with other scientists, students and technicians at the company and the university.
Responsibilities
- Independently drive your own research project
- Present your research results at internal and external meetings
- Disseminate your results in the form of scientific papers and the final PhD thesis
What you bring as a PhD student
- MSc student or recent graduate with a degree of thesis in the broad field of Neuroscience
- Meet the requirements for enrolment as a PhD student at a Danish university and can start your PhD no later than December 2027
- Be passionate about neuroscience, drug development and scientific communication
- Able to attend an interview during February or March 2027, presentation training on April 8th and 22nd 2027 and participate in the Brain Battle finale on April 29th, 2027, in person at the Lundbeck headquarters in Valby, Denmark
- Be able to work independently to drive your research project and seek guidance when needed
- Organizational skills to plan and report on experiments
- Collaborative and team-playing skills and actively seeking dialogue with your colleagues
- A positive mind-set
- Fluent in written and spoken English
Requirements
- MSc student or recent graduate with a degree of thesis in the broad field of Neuroscience
- Meet the requirements for enrolment as a PhD student at a Danish university and can start your PhD no later than December 2027
- Passionate about neuroscience, drug development and scientific communication
- Able to attend an interview during February or March 2027, presentation training on April 8th and 22nd 2027 and participate in the Brain Battle finale on April 29th, 2027, in person at the Lundbeck headquarters in Valby, Denmark
- Able to work independently to drive your research project and seek guidance when needed
- Organizational skills to plan and report on experiments
- Collaborative and team-playing skills and actively seeking dialogue with your colleagues
- A positive mind-set
- Fluent in written and spoken English
Benefits
- Fully funded PhD project
- Professional scientific communication training
- Development opportunities
- Well-being initiatives
Company overview
Lundbeck is a global pharmaceutical company specializing exclusively in brain diseases, with over 70 years of neuroscience expertise. Founded in 1915 in Copenhagen, Denmark, the company has established itself as one of the world's leading innovators in treatments for central nervous system disorders. Lundbeck focuses on developing and commercializing therapies for conditions including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and migraine. With approximately 5,000+ employees worldwide and operations in more than 50 countries, the company maintains production facilities in Denmark, France, and Italy, with research centers in Denmark and the United States. Lundbeck's portfolio includes some of the world's most widely prescribed therapies for brain diseases, reaching over 7 million people daily. The company is publicly traded on Nasdaq Copenhagen, with the Lundbeck Foundation holding approximately 70% ownership. Lundbeck's commitment to neuroscience research and patient-centered innovation has positioned it as a key player in addressing the complex challenges of brain health globally.